顺铂不同给药途径联合紫杉醇静脉滴注治疗晚期卵巢癌的疗效和不良反应

Efficacy and adverse reactions of different cisplatin methods combined paclitaxel intravenous drip in advanced ovarian cancer

目的探讨顺铂不同给药途径联合紫杉醇静脉滴注治疗晚期卵巢癌的疗效和不良反应发生情况。方法选取2012年8月至2013年8月间收治的84例晚期卵巢癌患者,按照就诊顺序分为观察组和对照组,每组42例。观察组患者采用顺铂腹腔灌注联合紫杉醇静脉滴注治疗,对照组患者采用顺铂静脉滴注联合紫杉醇静脉滴注治疗,观察并比较两组患者的临床疗效及不良反应的发生情况。结果观察组患者有效率和控制率分别为66.7%和88.1%,显著高于对照组的47.6%和64.3%,差异均有统计学意义（P〈0.05）。两组患者不良反应主要为骨髓抑制、消化系统反应和脱发等,两组患者不良反应发生率差异均无统计学意义（P〉0.05）。不良反应均属Ⅰ-Ⅱ级,对症处理后均有所缓解。结论采用紫杉醇静脉滴注联合顺铂腹腔灌注的给药方式治疗晚期卵巢癌疗效更好,不良反应均可耐受,具有较高的临床应用价值。

Objective To observe the efficacy and adverse reactions of different cisplatin methods combined paclitaxel intravenous drip with advanced ovarian cancer. Methods Totally 84 advanced ovarian cancer patients were enrolled in the study and randomly divided into the researsh group and the control group. The research group were given intraperitoneal perfusion of cisplatin combined intravenous drip treatment. The control group were treated with cisplatin combined intravenous drip treatment. After treatment,the efficacy and adverse reactions of the two groups were observed. Results After treatment,the total effectiveness and control rate of reserach group was 66. 7% and 88. 1%,were significantly higher than47. 6% and 64. 3% in the control group,with significant difference（ P〈0. 05）. The main adverse reactions were bone marrow depression,digestive system reactions etc. The incidence of adverse reaction between the two groups showed no statistical significance（ P〈0. 05）,and the adverse reactions were mainly grade Ⅰ - Ⅱ,eased after symptomatic treatment. Conclusion Using intravenous drip combined cisplatin peritoneal perfusion in the treatment of advanced ovarian cancer has better curative efficacy,and the adverse reactions are endurable. It has high clinical value.